Sareum Holdings (GB:SAR) has released an update.
Sareum Holdings PLC has successfully raised an additional £1 million through the issuance of new shares, further boosting its financial resources to advance its lead kinase inhibitor programs targeting autoimmune diseases and cancer. The funds will support the progression of SDC-1801 towards Phase 2 clinical trials and enhance the preclinical development of SDC-1802. This strategic move is expected to increase the potential value of these programs, attracting interest from potential license partners.
For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.
